Role of Reactive Oxygen Species-elicited Apoptosis in the Pathophysiology of Mitochondrial and Neurodegenerative Diseases Associated With Mitochondrial DNA Mutations  by Liu, Chun-Yi et al.
J Formos Med Assoc | 2009 • Vol 108 • No 8 599
More than 100 mutations of mitochondrial DNA
(mtDNA) are associated with human diseases, in-
cluding mitochondrial myopathy, encephalomy-
opathy, deafness, and mitochondrial diabetes.1
Most of these mtDNA mutations are present at
high levels (> 80%) in the affected tissues of pa-
tients with one of these mitochondrial diseases.
On the other hand, some of these pathogenic mu-
tations of mtDNA, especially the 4977-bp dele-
tion and A3243G transition, have been found to
accumulate with age in post-mitotic tissues of
elderly subjects.2 It has been established that path-
ogenic mtDNA mutations can cause mitochon-
drial dysfunction and enhance oxidative stress,
which in turn lead to apoptosis in affected tissues
and primary culture of human cells that harbor
mtDNA mutations. We contend that reactive oxy-
gen species (ROS)-elicited susceptibility of mutant-
mtDNA-containing human cells to apoptosis may
play a role in the pathogenesis and progression of
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Role of Reactive Oxygen Species-elicited
Apoptosis in the Pathophysiology of
Mitochondrial and Neurodegenerative
Diseases Associated With Mitochondrial
DNA Mutations
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A wide spectrum of pathogenic mutations of mitochondrial DNA (mtDNA) has been demonstrated to
cause mitochondrial dysfunction and overproduction of reactive oxygen species (ROS), in relation to 
mitochondrial and neurodegenerative diseases. Our previous studies have shown that large-scale dele-
tions of mtDNA not only serve as an indicator of oxidative damage, but also result in greater susceptibility
of human cells to apoptosis triggered by UV irradiation and other apoptotic stimuli. In this review, we
focus on the involvement of mtDNA-mutation-associated oxidative stress and susceptibility to apoptosis
in the pathophysiology of mitochondrial and neurodegenerative diseases. Different lines of research have
provided concordant data to suggest that the mtDNA-mutation-elicited energy insufficiency and enhanced
oxidative stress and damage lead to cell dysfunction, and increase the susceptibility of affected cells to
apoptosis in patients with these diseases. Moreover, accumulating experimental evidence has shown that
antioxidant therapy is a good strategy for decreasing intracellular ROS and alleviating oxidative-stress-
induced apoptosis in cells of patients that harbor pathogenic mtDNA mutations. [J Formos Med Assoc
2009;108(8):599–611]
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some types of mitochondrial and neurodegenera-
tive diseases.
Mitochondria as a Power House and 
ROS Generator
Mitochondria are responsible for production of
ATP, through respiration and oxidative phosphor-
ylation, to supply the energy needs for cellular
functions.3 Under normal physiological condi-
tions, 1–2% of molecular oxygen consumed by
mammalian cells is metabolized to ROS via elec-
tron leakage from the mitochondrial electron
transport chain. Therefore, mitochondria are a
major source of endogenous ROS in human and
animal cells.4,5 It has been demonstrated that the
production or accumulation of ROS is increased
when the mitochondrial respiratory chain is im-
paired by chemical compounds (e.g. respiratory
inhibitors),6,7 or pathogenic mutations in mito-
chondrial genes that are involved in the biosyn-
thesis of polypeptides that constitute respiratory
enzymes.1,8 The overproduction of ROS from dys-
functional mitochondria may directly cause oxida-
tive damage to cellular macromolecules, such as
lipids, proteins and nucleic acids,8 and in turn,
lead to membrane structural instability, accumula-
tion of unfolded and misfolded proteins, and
DNA mutations. On the other hand, ROS can ac-
tivate numerous signaling pathways that result in
alteration of gene expression profiles and culmi-
nate in different outcomes.9
Mitochondrial Role in Apoptosis
Besides serving as the major energy producer,
mitochondria also play a critical role in the regu-
lation of apoptosis, and act as a major switch 
to initiate apoptosis in mammalian cells.10 The
switch is believed to involve the release of several
apoptotic proteins, such as apoptosis-inducing fac-
tor (AIF), Smac/DIABLO and cytochrome c, from
the mitochondria through the opening of mito-
chondrial permeability transition pores (mtPTPs).
After being released from mitochondria, cyto-
chrome c forms a multimeric complex with Apaf-1
(apoptotic protease activating factor-1), which
activates procaspase-9 to activate procaspase-3 and
other cytosolic enzymes that lead the cells to apo-
ptosis. Smac/DIABLO is another mitochondrial
protein that can inhibit the function of inhibitor
of apoptotic proteins, and thereby allows the 
activation of caspase-9 on the apoptosome.11–13
AIF is translocated to the nucleus and participates
in the destruction of chromatin, and DNA frag-
mentation.14 The dynamic change in antiapoptotic
and proapoptotic proteins of the Bcl-2 family on
the mitochondrial outer membrane is also in-
volved in the mitochondrial permeability transi-
tion and thereby regulates the apoptotic process.15
Mitochondria are also an important mediator in
the amplification of the apoptotic signals from
the death receptors, through the caspase-8-
mediated truncation of Bid.14,16,17 Cardiolipin is
a polyunsaturated-fatty-acid-rich phospholipid that
is present only in mitochondria, and is embed-
ded primarily in the mitochondrial inner mem-
brane. ROS-induced peroxidation of cardiolipin
may alter the fluidity and other biophysical proper-
ties of mitochondrial membranes, and induce a
decrease in the activity of complexes III18 and IV,19
and dissociation of cytochrome c.20 Oxidative-
stress-elicited DNA damage increases the stability
and activity of p53 to alter the expression profiles
of several apoptosis-related genes, including pro-
apoptotic proteins such as Bax and Puma, which
promote cytochrome c release and subsequent
activation of the caspase cascade.21 In addition,
4-hydroxynonenal (4-HNE), a toxic end-product
of lipid peroxidation, not only conjugates with
other macromolecules to disrupt their biological
functions, but also emerges as an important sec-
ond messenger to trigger stress-induced apopto-
sis.22 Therefore, defects in mitochondrial energy
production and a chronic increase in intracellular
ROS and oxidative stress may activate the opening
of mtPTPs and initiate the apoptotic cascades.23
Moreover, apoptosis is a highly organized and
orchestrated type of cell death, which is involved
in embryonic development, immune responses,
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and many other physiological functions in hu-
mans and animals. Dysregulation of the cell-death
process is associated with aging, cancer, autoim-
mune disease, and several degenerative diseases.1
Mutations of mtDNA in Mitochondrial
and Neurodegenerative Diseases
mtDNA is the major target of ROS 
produced by mitochondria
mtDNA is located near the inner membrane where
ROS are produced as a byproduct of mitochon-
drial respiration, and is one of the major imme-
diate targets of ROS that leads to oxidative damage
and subsequent mutations. Furthermore, the lack
of protective histones, and inefficient DNA repair
systems result in a higher frequency of mutation
and oxidative damage to mtDNA compared with
that of nuclear DNA. These, as a whole, lead to
defects in mitochondrial respiration and oxida-
tive phosphorylation, ROS overproduction, and
progressive functional decline of affected cells.8,24
Association of mtDNA mutations and
mitochondrial diseases
A wide spectrum of mtDNA mutations, which in-
clude point mutations, large-scale deletions, small
insertions and tandem duplications, are associated
with mitochondrial diseases, and most of them
have been demonstrated to cause mitochondrial
dysfunction.1,25 Neurogenic muscle weakness,
ataxia, and retinitis pigmentosa (NARP), Leigh
syndrome, and Leber’s hereditary optic neuropa-
thy (LHON) are associated with point mutations
in the protein-coding genes. Point mutations in
tRNA genes are linked to mitochondrial myopa-
thy, encephalopathy, lactic acidosis, and stroke-
like episodes (MELAS), and myoclonic epilepsy
with ragged-red fibers (MERRF) syndrome. Large-
scale deletions, including the most common
4977-bp deletion, are responsible for sporadic
mitochondrial myopathy and encephalomyopa-
thy, including chronic progressive external oph-
thalmoplegia (CPEO), Kearns–Sayre syndrome
(KSS) and Pearson’s syndrome.
It is noteworthy that the 4977-bp deletion is
located in the major arc between two origins of
replication (OH and OL), and removes seven genes
for polypeptides and five tRNA genes. Several
mechanisms have been proposed to clarify the for-
mation of 4977-bp-deleted mtDNA, including
replication error and inefficient repair of damaged
mtDNA.26–29 The mutations elicited during the
repair of damaged mtDNA may explain the ob-
servations that mtDNA deletions are induced in
cultured human cells by singlet oxygen, UV irra-
diation, cigarette smoking, and ionizing irradia-
tion.30–32 It has been established that the content
of the oxidative DNA damage, indicated by the
level of 8-hydroxy 2’-deoxyguanosine (8-OHdG),
is correlated with the proportion of the deleted
mtDNA,33 which indicates that oxidative stress
and the ensuing DNA damage play an important
role in large-scale deletions of mtDNA. This also
supports the idea that the 4977-bp deletion of
mtDNA not only is a pathogenic mutation of mi-
tochondrial diseases, but also serves as an indica-
tor of oxidative damage in human cells.8
Accumulation of mtDNA deletions in
neurodegenerative disease
A number of groups have investigated the role of
large-scale deletions of mtDNA in neurodegener-
ative diseases, and found that the 4977-bp-deleted
mtDNA accumulates in large quantities in high-
energy-demand tissues of patients with some types
of these diseases. Ro et al analyzed the 4977-bp-
deleted mtDNA in muscle specimens from 36 pa-
tients with sporadic amyotrophic lateral sclerosis
(ALS) and 69 age-matched controls with other neu-
romuscular disorders, and found that the frequency
of occurrence and average level of the 4977-bp-
deleted mtDNA in the ALS patients were signifi-
cantly higher than those in the controls.34 Several
studies have demonstrated that mitochondrial
function, especially the activity of cytochrome c
oxidase (COX), is decreased in brain tissues of
patients with Alzheimer’s disease (AD).35,36 The
content of 4977-bp-deleted mtDNA in brain tis-
sue samples taken from AD patients with an av-
erage age of 68 years was about 6.5-fold higher
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than that in normal subjects with an average age
of 66 years.37 AD patients who died prior to age
75 years had four times more abundant 4977-
bp-deleted mtDNA than those who died after age
75 years. It has been suggested that mitochondrial
respiratory dysfunction that results from the com-
mon deletion may play a role in the progression
and pathophysiology of AD.38 On the other hand,
Parkinson’s disease (PD) has been reported to be
associated with deficiency of the respiratory en-
zyme complex I. Laser microdissection has been
used to provide evidence for the clonal expan-
sion of 4977-bp-deleted mtDNA to high levels
within substantia nigra neurons in patients with
PD.39,40 It has been found that neurons with
COX deficiency contain a high proportion of
mtDNA with the 4977-bp deletion, which indi-
cates that mitochondrial dysfunction is caused by
pathogenic mtDNA mutations. Therefore, tissues
with a high-energy demand are more susceptible
to mtDNA-mutation-elicited mitochondrial dys-
function in the progression of neurodegenerative
diseases.
ROS and Susceptibility to Apoptosis in
Patients With Mitochondrial Diseases
Oxidative stress in mitochondrial diseases
Most of the pathogenic mtDNA mutations have
been demonstrated to cause defects in the mito-
chondrial respiratory chain, which lead to over-
production of ROS in the mitochondria.1,25
Piccolo et al41 found increased levels of lipid per-
oxides and fluorescent adducts of aldehyde with
plasma proteins, and decreased concentration of
reduced glutathione (GSH) in the blood of pa-
tients with CPEO syndrome. Marked granular dis-
tributions of oxidative-damage markers, 8-OHdG
and 4-HNE, have been observed in the COX-
negative, ragged-red fibers from patients with mi-
tochondrial diseases.42 Therefore, increased oxida-
tive stress elicited by mitochondrial dysfunction
in the affected tissues plays an important role in
the pathogenesis and progression of mitochon-
drial diseases.
Apoptosis in affected tissues from patients
with mitochondrial diseases
The role and involvement of apoptosis in the
pathogenesis of mitochondrial diseases associ-
ated with mutated mtDNA has received increas-
ing attention in recent years. Mirabella et al
investigated apoptosis in muscle biopsies of 36
patients who carried different mtDNA mutations,
and found that apoptotic features (e.g. TUNEL-
positive staining and immunohistochemical stain-
ing of caspase-3, p75 and Fas) were localized
mainly in COX-negative muscle fibers that har-
bored a high percentage of single mtDNA dele-
tions (> 40%) or point mutations in tRNA genes
(> 70%).43 In another study, muscles in patients
with MELAS, CPEO and MERRF were found to
have only very small numbers of TUNEL-positive
myonuclei: 0.13±0.10%, 0.15±0.14% and 0.04±
0.09%, respectively.44 However, Bax and Apaf-1
expression and cytochrome c release from mito-
chondria were noted and caspase-3 activation
was detected in 9.0±3.7%, 12.0±4.4% and 12.4±
3.8% of ragged-red fibers in patients with MELAS,
CPEO and MERRF, respectively, but not in mus-
cles of healthy subjects. Umaki et al42 reported
that a pronounced granular appearance of 8-
OHdG, 4-HNE, manganese superoxide dismu-
tase (Mn-SOD), cytochrome c and DNase I was
detected in the COX-negative, ragged-red fibers
of patients with mitochondrial diseases, and that
TUNEL-positive signals were found not only in
myonuclei, but also in subsarcolemmal regions
of the muscle. Moreover, it was found that cyto-
chrome c was increased in the cytosol of patient’s
muscles and that DNase I was accumulated in
the mitochondria compared with normal mus-
cles.42 An in situ approach was employed to ad-
dress the relationship between apoptosis and
respiratory function defects, ragged-red fibers
and mtDNA mutation load, and the results indi-
cated that apoptosis was associated with a high
proportion of mtDNA mutation in muscle with
ragged-red fibers.45 These studies support the 
hypothesis that apoptosis plays a key role in the
pathogenesis of mitochondrial diseases associ-
ated with mtDNA mutations. However, further
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studies are needed to provide more solid 
evidence.
ROS and Susceptibility to Apoptosis in
Patients With Neurodegenerative
Diseases
Oxidative stress in neurodegenerative
diseases
In addition to the accumulation of ROS-elicited
deleted mtDNA described above, many studies
have found increased levels of lipid peroxidation
markers, including malondialdehyde and 4-HNE,
in the brain tissues of AD and PD patients and in
the cerebrospinal fluid of ALS patients. More-
over, protein carbonylation and nitration were
also elevated in the Lewy body of patients with
PD, the hippocampus and neocortex of AD pa-
tients, and motor neurons of patients with ALS.46
Recent studies on PD have revealed that a number
of PD-associated proteins, including α-synuclein,
Parkin, DJ-1, PINK1, LRRK2 and HTR2A are local-
ized in the mitochondria under certain condi-
tions, and that pathogenic mutations in some of
these proteins lead to increased sensitivity to 
oxidative stress and apoptotic inducers.47,48
Apoptosis in the brains of patients with
neurodegenerative diseases
Besides mitochondrial dysfunction and oxida-
tive stress, it has been established that apoptosis
is associated with the pathogenesis of neurode-
generative diseases. The brains of AD patients ex-
hibit elevated levels of DNA fragmentation, Bax
and caspase-3 activation.49,50 Research has shown
that activation of caspases and caspase-mediated
cleavage of the amyloid precursor protein and tau
protein facilitates the production of β-amyloid
(Aβ) and the formation of neurofibrillary tan-
gles.51 Moreover, deficiency of cyclophilin D, an
integral part of the mtPTPs, not only protected
neurons from Aβ- and oxidative-stress-induced
cell death, but also ameliorated learning and
memory defects in an AD mouse model.52 These
observations suggest that mitochondria-mediated
apoptosis plays a key role in the pathophysiol-
ogy of AD.
The role of apoptosis in PD has been substan-
tiated by the observation of an increase in the num-
ber of TUNEL-positive neurons in the brains of
PD patients.53 Bax has been shown to accumulate
in the melanized substantia nigra pars compacta
(SNpc) neurons that contain ubiquitin-positive
Lewy bodies in PD patients, although there is no
significant difference in Bax activation of post-
mortem brains between PD patients and healthy
subjects. Furthermore, all melanized SNpc neu-
rons in PD patients with activated caspase-3 are
also immunoreactive for Bax.54 Another group
has observed that the amount of Bax and activity
of caspase-3 are increased greatly in melanized
neurons of the substantia nigra of PD patients
compared with those of healthy subjects.55 More-
over, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP) treatment causes apoptosis of nigral
dopaminergic neurons through cytochrome c
release and caspase activation.56,57 It has been re-
ported that Bax is highly expressed in the substan-
tia nigra of mice after MPTP administration and
that its ablation attenuates MPTP-induced apo-
ptosis, which indicate that Bax plays a critical role
in MPTP neurotoxicity and pathogenesis of PD.58
Response of Cybrids to Apoptotic Stimuli
In order to study the relationship between mtDNA
genotype and phenotype, a number of investiga-
tors have established, by cytoplasmic fusion, cy-
brids that harbor different mtDNA mutations that
are related to mitochondrial and neurodegenera-
tive diseases.59,60 We have conducted a series of
studies on UV- or staurosporine (STS)-induced
apoptosis of cybrids that harbor mtDNA with
A3243G transition, A8344G transition, or 4977-
bp or 4366-bp deletions, and found that mtDNA
mutation enhances the sensitivity of human cells
to apoptosis.61–63 These findings are consistent
with the results obtained from treatment of cy-
brids that harbor 4977-bp-deleted mtDNA with
apoptotic stimuli such as H2O2 and TRAIL.64,65
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A caspase-3 activity assay has revealed that cybrids
that contain 4977-bp-deleted mtDNA are more
sensitive to STS or UV irradiation compared with
those with point mutations in the tRNA gene of
mtDNA.61 This is consistent with clinical obser-
vations that a lower proportion of mtDNA with
large-scale deletion is sufficient to cause the onset
of mitochondrial diseases, but it requires a much
higher level of mtDNA with a point mutation.66
We have also demonstrated that the activation of
caspase-8 is an upstream event that amplifies the
apoptotic signals by proteolytic cleavage of Bid,
which in turn trigger cytochrome c release and
lead the mutant cybrids to apoptosis.63 Moreover,
the 4977-bp deletion of mtDNA increases the
sensitivity of human cells to UV-induced apoptosis
in a quantitative manner, through cytochrome c
release from mitochondria, and caspase-3 activa-
tion.63 Under metabolic stress induced by cultur-
ing cells in galactose medium, LHON cybrids that
harbor mtDNA mutations that affect different
subunits of complex I (G3460A/ND1, G11778A/
ND4, T14484C/ND6) are triggered to undergo
cell death characterized by several apoptotic hall-
marks, such as chromatin condensation and nu-
clear DNA laddering.67 The increased release of
cytochrome c into the cytosol in LHON cybrids
compared with control cybrids suggests that mi-
tochondria are involved in the activation of the
apoptotic cascade.67 Similarly, cybrids that contain
LHON mutations also display increased suscep-
tibility to apoptosis induced by Fas or rote-
none.68,69 In addition, cybrids that harbor the
T8993G and T9176G mutations in the ATPase 6
gene associated with maternally inherited Leigh
syndrome are highly susceptible to apoptosis in-
duced by tumor necrosis factor-α or STS.70 These
studies on cybrids have provided solid evidence
to support the notion that point mutation and
deletion of mtDNA render human cells more sus-
ceptible to apoptosis induced by different apo-
ptotic stimuli (Table).
A similar approach of cytoplasmic fusion has
also been used to establish cybrids of neurode-
generative diseases, which utilize SH-SY5Y, NT2
and A549 cells as the host.71,72 PD and AD cybrids
display reduced activity of complexes I and IV,
respectively, decreased ATP content, increased oxi-
dative stress and damage, and enhanced suscep-
tibility to MPTP or Aβ, and are characterized by the
accumulation of apoptotic markers.71–74 Taking
these cybrid studies together, we suggest that 
mitochondrial dysfunction and mtDNA-mutation-
induced apoptosis are involved in the manifesta-
tion of conditions such as muscle wasting and
neurological disorders in patients with mitochon-
drial and neurodegenerative diseases, respectively.
Animal Models for Diseases Caused by
mtDNA Mutations
Several laboratories have developed animal models
to study the roles and mechanisms of nuclear
DNA and mtDNA mutations in the pathogenesis
of degenerative diseases. D257A mice with a mu-
tant form of mtDNA polymerase γ display striking
premature aging phenotypes, including reduced
life span, hair loss, graying hair, kyphosis, loss of
bone mass, loss of intestinal crypts, progressive de-
crease in circulating red blood cells, and weight
loss.75,76 These mice show accelerated accumula-
tion of mtDNA mutations in most somatic tissues,
and the well-correlated expression of apoptotic
markers, such as caspase-3 activation and TUNEL-
positive staining, particularly in tissues character-
ized by rapid cell turnover.76,77 These studies
suggest that mtDNA mutations indeed accelerate
the occurrence of apoptotic behavior in mammals.
On the other hand, Inoue et al generated “mito-
mice” that harbor pathogenic 4696-bp-deleted
mtDNA, which spans from tRNALeu to ND5, sim-
ilar to the 4977-bp deletion of human mtDNA, by
direct introduction of mitochondria with deleted-
mtDNA into mouse zygotes.78 Mito-mice mani-
fest several symptoms of mitochondrial diseases,
such as low body weight, lactic acidosis, system
ischemia, hearing loss, renal failure, and male in-
fertility,79 and the deleted mtDNA accumulates
with age in somatic tissues.80 Focusing on male
infertility, the group found that deleted-mtDNA-
elicited mitochondrial respiration defects can 
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induce oligospermia, asthenozoospermia, and mei-
otic arrest at the zygotene stage, as well as en-
hanced apoptosis.81 Additionally, other mice models
with deficiencies in adenine nucleotide translo-
cator 1, Mn-SOD or mitochondrial transcription
factor A show several mitochondrial-disease-like
phenotypes.82 These studies on animal models
have demonstrated that mtDNA mutations and
mitochondrial dysfunction can sensitize the ani-
mals to apoptotic markers, symptoms of prema-
ture aging, and degenerative and mitochondrial
diseases.
Oxidative stress and apoptosis in human diseases
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Table. Human osteosarcoma 143B-derived cybrids for study of mtDNA-mutation-induced susceptibility to apoptotic stimuli
and antioxidants
Type of mtDNA mtDNA gene 
Disease
Apoptotic 
Antioxidant Apoptotic marker Reference
mutation (position) inducer
A3243G tRNALeu(UUR) MELAS STS, UV – Caspase-3 activation 61
transition
A8344G tRNALys MERRF STS, UV – Caspase-3 activation 61
transition
4366 bp np 9579–13944 CPEO, KSS UV CoQ10 Viability, caspase-3 62
deletion activation, cytochrome
c release, DNA 
fragmentation
4977 bp np 8469–13447 CPEO, KSS STS – Viability, caspase-3 61
deletion activation, D4-GDI
cleavage, DNA
fragmentation
UV CoQ10, NAC Viability, activation of 61–63
caspase-3, -8 or -9,
D4-GDI cleavage, 
Bid cleavage, 
cytochrome c release,
DNA fragmentation
H2O2 Melatonin, CoQ10, Viability, cytochrome 64
vitamin E c release
H2O2, – Viability, caspase-3 65
TRAIL activation
G3460A ND1 LHON Fas – Viability, annexin V 68
transition stain, caspase-3
G11778A ND4 activation, DNA
transition fragmentation
T14484C ND6 Galactose Mn-SOD Viability, chromatin 67, 88
transition condensation, DNA
fragmentation,
cytochrome c release
Rotenone GSH Viability 69
T8993G ATPase 6 MILS TNF-α, STS NAC, CoQ10, Annexin V stain, 70
transversion L-acetyl-carnitine chromatin 
T9176G condensation
transversion
mtDNA = mitochondrial DNA; MELAS = mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes; MERRF = myoclonic epilepsy
with ragged-red fibers; CPEO = chronic progressive external ophthalmoplegia; KSS = Kearns–Sayre syndrome; LHON = Leber’s hereditary optic neuropa-
thy; MILS = maternally inherited Leigh syndrome; CoQ10 = coenzyme Q10; NAC = N-acetylcysteine; Mn-SOD = manganese superoxide dismutase; GSH =
glutathione; STS = staurosporine; TNF = tumor necrosis factor; UV = ultraviolet light.
Antioxidant Therapy for Mitochondrial
Diseases and Neurodegenerative
Diseases
In previous studies on cybrids that harbor 4977-
bp-deleted mtDNA, we have observed that mito-
chondrial respiratory function is decreased, and
the levels of ROS and oxidative damage to DNA
and lipids are increased, in relation to the level
of 4977-bp-deleted mtDNA.83,84 These results
are consistent with the findings that the intracel-
lular levels of ROS and the 8-OHdG in skin fi-
broblasts of CPEO patients are higher than those
of controls.85 As described above, distinct apop-
totic features have been observed in the affected
muscle fibers that carry pathogenic mtDNA mu-
tations,42–45 and in mutant cybrids treated with
different apoptotic stimuli.61–63 Therefore, we con-
tend that mtDNA-elicited ROS overproduction
plays a key role in the susceptibility to apoptosis
of human cells that harbor a pathogenic mutation
of mtDNA triggered by various stimuli. We and our
collaborators have demonstrated that coenzyme
Q10 (CoQ10) and melatonin are effective in atten-
uating apoptosis of human cells that harbor the
4977-bp deletion of mtDNA.62,64 Recently, we
have observed that N-acetylcysteine (NAC) treat-
ment effectively decreases H2O2 production in a
dose-dependent manner, and attenuates sensitiv-
ity to UV-triggered apoptosis of cybrids that harbor
4977-bp-deleted mtDNA (unpublished data). In
similar studies, enhanced ROS production and de-
creased antioxidant defense capacities have been
observed in LHON cybrids that harbor mtDNA
mutations associated with LHON.86,87 GSH has
been found to protect cybrids from cell death in-
duced by treatment with tert-butyl hydroperoxide
or rotenone.69 Overexpression of Mn-SOD in
LHON cybrids also reduces the accumulation 
of ROS and attenuates metabolic-stress-induced
apoptosis.88 Moreover, it has been shown that
CoQ10 attenuates oxidative stress and damage,
increases complex I activity, and restores ATP to
control levels in PD cybrids.89 NAC treatment 
attenuates the accumulation of oxidative-stress
markers and enhanced apoptosis of AD cybrids.90
Therefore, inhibition of ROS overproduction by
antioxidants and free-radical-scavenging enzymes
may protect mutant cybrids from apoptosis trig-
gered by different stimuli (Table).
To date, there is no effective drug to prevent the
progression of mitochondrial and neurodegener-
ative diseases. Consequently, it is a rational ap-
proach to develop therapeutic agents that target
mitochondria and ROS, to protect cells from apop-
tosis and slow the progression of these diseases.
Based on the observations that CoQ10 and NAC
decrease intracellular ROS and alleviate oxidative-
stress-induced apoptosis in human cells that har-
bor pathogenic mtDNA mutations, we suggest that
antioxidant therapy is full of potential to become
a good therapeutic strategy.
Indeed, several antioxidants including CoQ10
have been undergoing clinical trials for patients
with mitochondrial or neurodegenerative dis-
eases. In addition to scavenging free radicals,
CoQ10 may enhance mitochondrial function by
stabilizing the mitochondrial inner membrane
and raising the efficiency of ATP synthesis. The
serum CoQ10 levels of some patients with mito-
chondrial diseases are significantly lower before
CoQ10 treatment than those of normal subjects
and increase significantly after administration of
CoQ10.91 It has been reported that CoQ10 attenu-
ates the fatigability of daily activities, and in-
creases endurance to exercise and global muscle
strength in some patients with mitochondrial
diseases,91 and improves the visual acuity in some
LHON patients.92 Moreover, other clinical studies
have demonstrated that CoQ10 therapy improves
the pancreatic β-cell function and attenuates the
symptoms of patients with MELAS, such as lactic
acidosis and stroke-like episodes.93,94 Currently,
CoQ10 is on the participant-recruited stage of a
phase III clinical trail for patients with mitochon-
drial diseases.95 A randomized, double-blind,
placebo-controlled study in patients with early
PD has revealed that CoQ10 is safe and well-
tolerated at dosages of up to 1200 mg/day, and
that it slows the progressive deterioration of func-
tion.96 However, another study has indicated that
CoQ10 does not display symptomatic effects in
C.Y. Liu, et al
606 J Formos Med Assoc | 2009 • Vol 108 • No 8
mid-stage PD.97 Therefore, a phase III clinical
trail of 1200 mg and 2400 mg CoQ10 is now un-
derway to verify whether it has symptomatic or
neuroprotective effects. Furthermore, as a poten-
tial neuroprotective agent, CoQ10 is also under-
going clinical trials in patients with AD, ALS, and
Huntington’s disease.98
Conclusion
It has been established that mitochondrial dys-
function and apoptosis play an important role in
the pathogenesis and progression of mitochon-
drial and degenerative diseases. In light of these
observations, we provide a hypothetical model
of mitochondrial role in these diseases (Figure).
The mtDNA mutation-elicited deficiency of mi-
tochondrial respiration and oxidative phospho-
rylation cause a progressive decline in ATP
synthesis and increased ROS formation and then
results in a vicious cycle. The overproduction 
of ROS from dysfunctional mitochondria may
directly cause oxidative damage to cellular macro-
molecules and in turn lead to alteration of their
biochemical and physiological functions, and
alter gene expression profiles to lead cells into
apoptosis. We believe that the mtDNA mutation-
elicited energy insufficiency and enhanced oxida-
tive damage may cause cell dysfunction, and that
the mtDNA mutation-induced susceptibility to
apoptosis in high energy-demand tissues is in-
volved in the manifestation and clinical progres-
sion of mitochondrial and neurodegenerative
diseases, respectively. Several clinical studies have
revealed the efficacy and amount of CoQ10 needed
for clinical treatment of mitochondrial and neu-
rodegenerative diseases. The abovementioned find-
ings support the notion that antioxidant therapy
is a potential therapeutic strategy for the treatment
of these diseases through attenuation of intra-
cellular ROS and alleviation of oxidative stress-
induced apoptosis in human cells that harbor
pathogenic mtDNA mutations.
Oxidative stress and apoptosis in human diseases
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Figure. The roles of mitochondria in mitochondrial and neurodegenerative
diseases. Pathogenic mtDNA mutations produce defective respiratory
subunits, which are assembled to form an inefficient mitochondrial
respiration and oxidative phosphorylation system. Mitochondrial dysfunction
cause reduced ATP synthesis and ROS overproduction. Overproduction of 
ROS from dysfunctional mitochondria may directly cause oxidative damage 
to cellular macromolecules, such as lipids, proteins and nucleic acids, and in
turn lead to instability of membrane structure, accumulation of unfolded 
and misfolded proteins, and DNA mutations. Oxidative stress and ensuing
DNA damage accelerate the formation of mtDNA mutations through
replication error and repair of damaged mtDNA. Moreover, ROS and 4-HNE
also activate numerous ROS-responsive signaling pathways that result in
alteration of gene-expression profiles, which render cells more prone to
apoptosis. During the process of aging and progression of degenerative
diseases, mtDNA mutations and oxidative damage accumulate and lead to
progressive decline in bioenergetic function and enhanced ROS formation,
which culminates in a vicious cycle. The mtDNA-mutation-elicited energy
insufficiency and enhanced oxidative damage cause cell dysfunction, and
increase the susceptibility to apoptosis in tissues of high energy demand of
patients with mitochondrial or neurodegenerative diseases. Most importantly,
mtDNA-mutation-induced apoptosis is involved in the manifestation and
clinical progression of muscle wasting and neurological disorders in a 
number of these debilitating diseases. mtDNA = mitochondrial DNA; 
ROS = reactive oxygen species; 4-HNE = 4-hydroxynonenal.
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